APA (7th ed.) Citation

Zhou, S., Liu, W., Zhou, C., Zhang, L., Xie, L., Xu, Z., . . . Shao, F. (2020). Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration. Cancer chemotherapy and pharmacology, 86(6), 719-730. https://doi.org/10.1007/s00280-020-04159-0

Chicago Style (17th ed.) Citation

Zhou, Sufeng, et al. "Mass Balance, Metabolic Disposition, and Pharmacokinetics of [14C]ensartinib, a Novel Potent Anaplastic Lymphoma Kinase (ALK) Inhibitor, in Healthy Subjects Following Oral Administration." Cancer Chemotherapy and Pharmacology 86, no. 6 (2020): 719-730. https://doi.org/10.1007/s00280-020-04159-0.

MLA (9th ed.) Citation

Zhou, Sufeng, et al. "Mass Balance, Metabolic Disposition, and Pharmacokinetics of [14C]ensartinib, a Novel Potent Anaplastic Lymphoma Kinase (ALK) Inhibitor, in Healthy Subjects Following Oral Administration." Cancer Chemotherapy and Pharmacology, vol. 86, no. 6, 2020, pp. 719-730, https://doi.org/10.1007/s00280-020-04159-0.